Navigation Links
Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
Date:1/19/2011

CAMBRIDGE, Mass., Jan. 19, 2011 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis (the spread of cancer cells to secondary locations). A cornerstone of Pervasis' oncology program, the company has entered into an exclusive patent license agreement with the Massachusetts Institute of Technology (MIT) for all discovery and development activities associated with cellular implants for cancer diagnosis, prognosis and treatment. In addition, supportive evidence from multiple preclinical studies demonstrates the powerful anti-angiogenic, anti-proliferative and anti-inflammatory properties of this endothelial cell-based approach in the presence of various solid tumor cancers, such as brain, lung, breast and prostate.

Pervasis, a clinical stage company based in Cambridge, Mass., is focused on developing breakthrough cell-based therapies that harness the healing power of the endothelium, the thin layer of cells that lines the interior surface of every blood vessel in the body. The company's other areas of clinical investigation include improving outcomes following common vascular surgical and interventional procedures, such as hemodialysis access, angioplasties, stents and peripheral and coronary bypass grafts -- the failures of which result in serious complications and a significant increase in medical costs.

"We are very excited to expand our focus to include the critical area of oncology," stated Frederic Chereau, president and chief executive officer of Pervasis. "We already have amassed a significant amount of data demonstrating the safety and efficacy of utilizing our novel cell-based approach to improve outcom
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
2. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
3. PTC Therapeutics President and CEO Elected AAAS Fellow
4. Resolvyx Pharmaceuticals and Celtic Therapeutics Enter Final Agreement in Ophthalmology
5. ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
6. Echo Therapeutics to Present at the OneMedForum 2011 Conference
7. Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002
8. Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis
9. Echo Therapeutics Receives Funding and Commitment of Approximately $5.5 Million
10. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 The Pulmonary Fibrosis ... data from more than 1,100 patients and families suffering ... Drug Administration (FDA) for the Patient-Focused Drug Development Meeting ... a new FDA initiative to seek patient input in ... therapeutic treatments. "We applaud the FDA for ...
(Date:9/16/2014)... , Sept. 16, 2014 Astellas announced ... of Business Communications & Advocacy, Urology in the ... Communications & Advocacy Margaret Long. In this role, Noland ... urology to patient and advocacy organizations, as well ... key strategic initiatives. Noland,s appointment is the latest ...
(Date:9/16/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... an underwritten registered public offering of shares of ... being offered by Aratana Therapeutics. ... book-running managers for the offering.  ...
Breaking Medicine Technology:PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 2PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 3PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting 4Christy Noland to Lead Urology Advocacy and Communications for Astellas 2Aratana Therapeutics, Inc. Announces Proposed Public Offering 2
... Oct. 11 Merial, the Animal Health division ... ), announced today that Merial Animal Health Co. (China) held ... located in the Nanchang Hi-tech Development Zone, China. Merial ... the Group,s first production facility in China has been in ...
... , EXTON, Pa., Oct. 9 Kensey Nash Corporation (Nasdaq: ... earnings results for its first quarter ended September 30, 2009 ... , Joe Kaufmann, President and CEO, will be ... 22, 2009 at 9:00 A.M. Eastern Time. , ...
Cached Medicine Technology:Merial invests US $70 million in Nanchang, China 2Merial invests US $70 million in Nanchang, China 3Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference 2
(Date:9/16/2014)... Paradigm Physical Therapy is proud to announce ... for their patients. Dry needling is a procedure that ... musculoskeletal problems. , In this invasive procedure, a solid ... and muscle to create a trigger point. Using repeated ... to deactivate and release the trigger point within seconds. ...
(Date:9/16/2014)... Florida (PRWEB) September 16, 2014 These new ... last 3 years to receive up to $10,000 in a ... program, as well as other state and federal programs, are ... to be paid back until you sell or move out ... is a 0% interest loan. There are no monthly payments ...
(Date:9/16/2014)... magnesium sulfate is routinely given to pregnant women at ... won,t provide any long-term benefits for infants. ... pregnant women, researchers in Australia found it had no ... those children when they were assessed at between 6 ... negate the fact that the drug is helpful in ...
(Date:9/16/2014)... able to predict when and how much various treatments ... part to new findings that researchers at Fox Chase ... Oncology,s 56th Annual Meeting on Tuesday, September 16. , ... completed by men diagnosed with prostate cancer, Fox Chase ... following each type of treatment, and by how much. ...
(Date:9/16/2014)... September 16, 2014 This year’s theme ... and Sustainable company Glen Mills, Pennsylvania, September 15, 2014- ... one of the fastest growing companies in the country, ... flower, shrub, and tree health-care by naturally decreasing disease ... development. Today it announced that it will hold its ...
Breaking Medicine News(10 mins):Health News:Paradigm Physical Therapy Introduces Dry Needling 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 3Health News:Holganix Holds 3rd Annual Bionutritional Summit in Louisville, Kentucky 2
... Calif., May 27 The Ensign,Group, Inc. (Nasdaq: ... Ensign(TM) group of,skilled nursing, rehabilitative care services and ... in the FBR Capital,Markets 12th Annual Spring Investor ... in New York City. Christopher Christensen, CEO, together ...
... provide the infrastructure for MRF,s collaborative ... ... 27 Collaborative Drug,Discovery, Inc. (CDD) announced today that its ... new drug,candidates, has been selected by the Myelin Repair Foundation ...
... infection following operations for which a "prophylactic" antibiotic is ... than it was just a decade ago, according to ... report their findings in the June 15 issue of ... that have been associated with severe infections, such as ...
... dad is more involved in baby,care than ever before. Whether ... basics, or a new dad to whom the dear wife ... to pack in the "diaper,dude":, The Moms on Call ... pediatric nurse moms, is a guidebook for new dads that ...
... study says , , TUESDAY, May 27 (HealthDay News) -- A ... in nonsmokers, researchers report. , The findings -- that certain ... lung cancer, regardless of whether he or she ever smoked ... said study author Dr. Ping Yang, of the Mayo Clinic. ...
... 27 Somanetics Corporation,(Nasdaq: SMTS ) announced today ... and Drug Administration (FDA) to expand the labeling for ... 510(k) will serve to support our ongoing efforts,in the ... said,Bruce Barrett, Somanetics, president and CEO. "First, the 510(k) ...
Cached Medicine News:Health News:The Ensign Group to Present at the FBR Capital Markets 12th Annual Spring Investor Conference on May 29th 2Health News:The Ensign Group to Present at the FBR Capital Markets 12th Annual Spring Investor Conference on May 29th 3Health News:Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership 2Health News:Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership 3Health News:Collaborative Drug Discovery and Myelin Repair Foundation Announce Partnership 4Health News:The balance shifts 2Health News:Father's Day is Almost Here: Two Pediatric Nurses, Moms, Offer Practical Guidebook & DVD for New Dads 2Health News:Common Genetic Variant Tied to Lung Cancer Risk 2Health News:Common Genetic Variant Tied to Lung Cancer Risk 3Health News:Somanetics Receives 510(k) Clearance From the FDA to Expand INVOS System Labeling 2
Featuring a secure and tamper-evident adhesive closure, computer-generated Smart ScanBand can be simultaneously printed with bar code information and programmed with RFID information....
Safe. Reliable. Baby-friendly. ,The Hugs infant protection system helps to protect your infants and children from the threat of abduction....
VerdaSee Portal ID is a family of solutions that provide automated tracking and tracing of assets as they enter or leave designated areas within a healthcare facility....
... Agility is positioned to support ... to reduce medication and other ... workflow for pharmacy support staff ... blood products, lab specimens and ...
Medicine Products: